Design and Expected Performance of the AGR-1 Fission Product Monitoring System (FPMS)

The US Department of Energy has embarked on a series of tests of TRISO-coated particle reactor fuel intended for use in the Very High Temperature Reactor (VHTR) as part of the Advanced Gas Reactor (AGR) program. The AGR-1 TRISO fuel experiment, currently underway, is the first in a series of eight fuel tests planned for irradiation in the Advanced Test Reactor (ATR) located at the Idaho National Laboratory (INL). The AGR-1 experiment reached a peak compact averaged burn up of 9% FIMA with no known TRISO fuel particle failures in March 2008. The burnup goal for the majority of the fuel compacts is to have a compact averaged burnup greater than 18% FIMA and a minimum compact averaged burnup of 14% FIMA. At the INL the TRISO fuel in the AGR-1 experiment is closely monitored while it is being irradiated in the ATR. The effluent monitoring system used for the AGR-1 fuel is the Fission Product Monitoring System (FPMS). The FPMS is a valuable tool that provides near real-time data indicative of the AGR-1 test fuel performance and incorporates both high-purity germanium (HPGe) gamma-ray spectrometers and sodium iodide [NaI(Tl)] scintillation detector-based gross radiation monitors. To quantify the fuel performance, release-to-birth ratios (R/B’s) of radioactive fission gases are computed. The gamma-ray spectra acquired by the AGR-1 FPMS are analyzed and used to determine the released activities of specific fission gases, while a dedicated detector provides near-real time count rate information. Isotopic build up and depletion calculations provide the associated isotopic birth rates. This paper highlights the features of the FPMS, encompassing the equipment, methods and measures that enable the calculation of the release-to-birth ratios. Some preliminary results from the AGR-1 experiment are also presented.

Download Full-text

Preliminary results of an on-Line, multi-spectrometer fission product monitoring system to support advanced gas reactor fuel testing and qualification in the advanced test reactor at the Idaho National Laboratory

2007 IEEE Nuclear Science Symposium Conference Record ◽

10.1109/nssmic.2007.4436445 ◽

2007 ◽

Cited By ~ 1

Author(s):

D. M. Scates ◽

J.K. Hartwell ◽

M.W. Drigert ◽

J.B. Walter

Keyword(s):

Fission Product ◽

Monitoring System ◽

National Laboratory ◽

Reactor Fuel ◽

Idaho National Laboratory ◽

Preliminary Results ◽

On Line ◽

Test Reactor

Download Full-text

The miR-21 potential of serving as a biomarker for liver diseases in clinical practice

Biochemical Society Transactions ◽

10.1042/bst20200653 ◽

2020 ◽

Vol 48 (5) ◽

pp. 2295-2305

Author(s):

Jiawei Zhang ◽

Dandan Li ◽

Rui Zhang ◽

Peng Gao ◽

Rongxue Peng ◽

...

Keyword(s):

Clinical Practice ◽

Liver Diseases ◽

Hepatic Disease ◽

Noninvasive Detection ◽

Diagnosis And Prognosis ◽

Expected Performance ◽

Potential Biomarker ◽

Disease Condition ◽

Complex Regulatory Network

The role of miR-21 in the pathogenesis of various liver diseases, together with the possibility of detecting microRNA in the circulation, makes miR-21 a potential biomarker for noninvasive detection. In this review, we summarize the potential utility of extracellular miR-21 in the clinical management of hepatic disease patients and compared it with the current clinical practice. MiR-21 shows screening and prognostic value for liver cancer. In liver cirrhosis, miR-21 may serve as a biomarker for the differentiating diagnosis and prognosis. MiR-21 is also a potential biomarker for the severity of hepatitis. We elucidate the disease condition under which miR-21 testing can reach the expected performance. Though miR-21 is a key regulator of liver diseases, microRNAs coordinate with each other in the complex regulatory network. As a result, the performance of miR-21 is better when combined with other microRNAs or classical biomarkers under certain clinical circumstances.

Download Full-text

Monitoring des Arzneimittelmissbrauchs 2006 bei Klienten von Suchtberatungsstellen (PHAR-MON)

SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice ◽

10.1024/2007.07.05 ◽

2007 ◽

Vol 53 (7) ◽

pp. 65-77 ◽

Cited By ~ 1

Author(s):

Susanne Roesner ◽

Heinrich Küfner

Keyword(s):

Monitoring System

Hintergrund und Zielsetzung: PHAR-MON ist ein Monitoring-System, das die auf dem deutschen Markt befindlichen Arzneimittel in ihrer Bedeutung für die Entwicklung von Missbrauch und Abhängigkeit in Suchtberatungsstellen überwacht. Methodik: Klienten ambulanter Beratungsstellen werden im Rahmen der Standarddokumentation zu ihrem Arzneimittelkonsum befragt und Fälle eines abhängigen Konsums, eines schädlichen Gebrauchs oder eines Missbrauchs in PHAR-MON dokumentiert. Ergebnisse: Im Jahr 2006 wurden insgesamt 448 Meldungen von 276 überwiegend alkohol- und drogenabhängigen Klienten in das Monitoring einbezogen. Tranquilizer vom Benzodiazepin-Typ wurden in allen Klientengruppen mit Anteilen zwischen 29,1 % und 35,3 % am häufigsten dokumentiert. An benzodiazepinabhängige Klienten werden zunehmend auch Nicht-Benzodiazepin-Hypnotika verordnet. Bei opioidabhängigen Klienten war im Zeitraum der letzten fünf Jahre ein Anstieg im missbräuchlichen Substitutionsmittelkonsum von 14,9 % auf 33,8 % zu verzeichnen. Schlussfolgerungen: Das Risiko gefährlicher Wechselwirkungen zwischen Arzneimitteln mit Alkohol und Drogen sollte stärker als bisher in die ärztliche Verordnungsentscheidung einbezogen werden.

Download Full-text